Your Good Partner in Biology Research

  1. 首頁(yè)
  2. 活性蛋白
  3. 其他
  4. Recombinant Human Glypican-3 (GPC3) (G537R), partial (Active)

Recombinant Human Glypican-3 (GPC3) (G537R), partial (Active)

In Stock
  • 中文名稱：
    人GPC3重組蛋白
  • 貨號(hào)：
    CSB-MP009705HU(M)
  • 規(guī)格：
    ￥1368
  • 圖片：
    • (Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.
    • Activity
      Measured by its binding ability in a functional ELISA. Immobilized human GPC3 (G537R) at 5 μg/ml can bind Anti-GPC3 recombinant antibody, the EC50 is 4.739-7.092 ng/ml. Biological Activity Assay
  • 其他：

產(chǎn)品詳情

  • 純度：
    Greater than 90% as determined by SDS-PAGE.
  • 內(nèi)毒素：
    Less than 1.0 EU/ug as determined by LAL method.
  • 生物活性：
    Measured by its binding ability in a functional ELISA. Immobilized human GPC3 (G537R) at 5 μg/ml can bind Anti-GPC3 recombinant antibody, the EC50 is 4.739-7.092 ng/ml.
  • 基因名：
  • Uniprot No.：
  • 別名：
    (GTR2-2)(Intestinal protein OCI-5)(MXR7)
  • 分子結(jié)構(gòu)：
  • 種屬：
    Homo sapiens (Human)
  • 蛋白長(zhǎng)度：
    Partial
  • 來(lái)源：
    Mammalian cell
  • 分子量：
    65.0 kDa
  • 表達(dá)區(qū)域：
    25-559aa(G537R)
  • 氨基酸序列
    QPPPPPPDATCHQVRSFFQRLQPGLKWVPETPVPGSDLQVCLPKGPTCCSRKMEEKYQLTARLNMEQLLQSASMELKFLIIQNAAVFQEAFEIVVRHAKNYTNAMFKNNYPSLTPQAFEFVGEFFTDVSLYILGSDINVDDMVNELFDSLFPVIYTQLMNPGLPDSALDINECLRGARRDLKVFGNFPKLIMTQVSKSLQVTRIFLQALNLGIEVINTTDHLKFSKDCGRMLTRMWYCSYCQGLMMVKPCGGYCNVVMQGCMAGVVEIDKYWREYILSLEELVNGMYRIYDMENVLLGLFSTIHDSIQYVQKNAGKLTTTIGKLCAHSQQRQYRSAYYPEDLFIDKKVLKVAHVEHEETLSSRRRELIQKLKSFISFYSALPGYICSHSPVAENDTLCWNGQELVERYSQKAARNGMKNQFNLHELKMKGPEPVVSQIIDKLKHINQLLRTMSMPKGRVLDKNLDEEGFESGDCGDDEDECIGGSGDGMIKVKNQLRFLAELAYDLDVDDAPRNSQQATPKDNEISTFHNLGNVH
  • 蛋白標(biāo)簽：
    N-terminal 6xHis-Myc-tagged
  • 產(chǎn)品提供形式：
    Lyophilized powder
    Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
  • 緩沖液：
    Lyophilized from a 0.2 μm filtered 20 mM Tris-HCl, 0.5 M NaCl, 6% Trehalose, pH 8.0
  • 復(fù)溶：
    We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final concentration of glycerol is 50%. Customers could use it as reference.
  • 儲(chǔ)存條件：
    Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
  • 保質(zhì)期：
    The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
    Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
  • 貨期：
    3-7 business days
  • 注意事項(xiàng)：
    Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
  • 產(chǎn)品描述：

    The gene fragment corresponding to amino acids 25-559 of the human glypican-3 (GPC3) is expressed in mammalian cells and then is fused with the 6xHis-Myc-tag at the N-terminus. The resulting protein has been validated to be an active protein in the functional ELISA. It can bind to the anti-GPC3 antibody, and the EC50 is 4.739-7.092 ng/ml. Its purity is greater than 92.4% measured by SDS-PAGE. On the gel, this protein migrated to the molecular weight band of 70-90 kDa. The endotoxin of this protein is less than 1.0 EU/ug determined by the LAL method. GPC3 is a cell-surface glycoprotein and has important functions in signaling including cell growth, embryogenesis, and differentiation. GPC3 upregulation has been found in hepatocellular carcinoma (HCC), while GPC3 is absent in normal and cirrhotic liver. GPC3 has recently been identified as a potential hepatocellular carcinoma (HCC) diagnostic and therapeutic target.

  • Datasheet & COA：
    Please contact us to get it.

產(chǎn)品評(píng)價(jià)

平均分:
5.0分 - 1 個(gè)評(píng)價(jià)

實(shí)驗(yàn)應(yīng)用：抗原, ELISA標(biāo)準(zhǔn)品

產(chǎn)品評(píng)價(jià)： GPC3是肝細(xì)胞癌(HCC)診斷和治療靶點(diǎn)，我們將GPC3用于抗體篩選過(guò)程中的對(duì)照，收到產(chǎn)品后我們進(jìn)行了純度檢測(cè)和結(jié)合活性檢測(cè)，純度確實(shí)高于標(biāo)準(zhǔn)水平，EC50為7.525-12.28 ng/ml，活性較好，最后篩到了理想的陽(yáng)性克??！整個(gè)實(shí)驗(yàn)很順利，說(shuō)明產(chǎn)品質(zhì)量確實(shí)不錯(cuò)，還會(huì)繼續(xù)購(gòu)買~~~

By 許老師

靶點(diǎn)詳情

  • 功能：
    Cell surface proteoglycan that bears heparan sulfate. Negatively regulates the hedgehog signaling pathway when attached via the GPI-anchor to the cell surface by competing with the hedgehog receptor PTC1 for binding to hedgehog proteins. Binding to the hedgehog protein SHH triggers internalization of the complex by endocytosis and its subsequent lysosomal degradation. Positively regulates the canonical Wnt signaling pathway by binding to the Wnt receptor Frizzled and stimulating the binding of the Frizzled receptor to Wnt ligands. Positively regulates the non-canonical Wnt signaling pathway. Binds to CD81 which decreases the availability of free CD81 for binding to the transcriptional repressor HHEX, resulting in nuclear translocation of HHEX and transcriptional repression. Inhibits the dipeptidyl peptidase activity of DPP4. Plays a role in limb patterning and skeletal development by controlling the cellular response to BMP4. Modulates the effects of growth factors BMP2, BMP7 and FGF7 on renal branching morphogenesis. Required for coronary vascular development. Plays a role in regulating cell movements during gastrulation.
  • 基因功能參考文獻(xiàn)：
    1. The areas under the receiver operating curve (AUROC) value, sensitivity and specificity of glypican 3 (GPC3) for hepatoblastoma (HB) pretreatment group versus all controls were all significantly lower than those of alpha-fetoprotein (AFP). PMID: 28378832
    2. GPC3 is operating through an intricate molecular signaling network. From the balance of these interactions, the inhibition of breast metastatic spread induced by GPC3 emerges. PMID: 30267212
    3. Its surface is modified with anti-GPC3 antibody. PMID: 29916268
    4. data suggest that transcriptionally targeted delivery of transgene in HCC cells can be achieved using the GPC3 promoter and this targeting strategy produces limited toxicity to normal liver cells PMID: 29563582
    5. High GPC3 expression is associated with Hepatocellular Carcinoma. PMID: 28429175
    6. Study demonstrated that GPC3 expression is inversely associated with glucose metabolism, suggesting that GPC3 may play a role in regulating glucose metabolism in hepatocellular carcinoma. PMID: 29398870
    7. the intravenous injection of SF-PL/siGPC3 into nude mice bearing subcutaneous human HepG2 xenografts effectively inhibited tumor growth and also increased the survival rates of animals. These results revealed the great potential of the PEI-modified liposomal nanomedicine carrying SF and siGPC3 to improve Hepatocellular carcinomatreatment PMID: 29106433
    8. Invasive hepatocellular carcinoma (HCC) samples and HCC cell lines with high metastatic potential exhibited higher MXR7 expression. Overexpression of MXR7 promoted epithelial-mesenchymal transition (EMT) progress, and MXR7 depletion repressed the EMT phenotype. Human MXR7 protein is a mediator of EMT and metastasis in HCC. PMID: 28812296
    9. Overexpression of GPC3 was significantly associated with poor prognosis in patients with hepatocellular carcinoma. PMID: 29901640
    10. These data show that glycanation and convertase maturation are not required for soluble mutant GPC3 to inhibit hepatocellular carcinoma cell proliferation. PMID: 29345911
    11. Data indicate that several microRNAs targeting the oncogenic functions of glypican-3 (GPC3). PMID: 28476031
    12. presence distinguishes aggressive from non-aggressive odontogenic tumors PMID: 27647326
    13. GPC3 as a potential metastasis suppressor gene and suggest its value as a prognostic marker in gastric cancer. PMID: 27259271
    14. In this study we systematically evaluated a series of CAR constructs targeting glypican-3 (GPC3), which is selectively expressed on several solid tumors. We compared GPC3-specific CARs that encoded CD3zeta (Gz) alone or with costimulatory domains derived from CD28 (G28z), 4-1BB (GBBz), or CD28 and 4-1BB (G28BBz). PMID: 27530312
    15. Data indicate that glypican-3 (GPC3) is an important regulator of epithelial-mesenchymal transition (EMT) in breast cancer, and a potential target for procedures against breast cancer metastasis. PMID: 27507057
    16. Glypican-3 overexpression in Wilms tumor correlates with poor overall survival. PMID: 28432433
    17. glypican-3 has a role in HBV-related hepatocellular carcinoma PMID: 27286460
    18. MOSPD1 is a possible candidate gene for DORV, probably in combination with GPC3. Further studies of the combined functions of MOSPD1 and GPC3 are needed, and identification of additional patients with MOSPD1 and GPC3 duplication should be pursued PMID: 28636109
    19. Glypican-3 is correlated with the clinical malignant behavior of hepatocellular carcinoma and its phenotype changes from positive to negative during tumor cells differentia- tion. PMID: 28087980
    20. The diagnostic sensitivity for hepatocellular carcinoma increased to 72.8% (206 of the 283) when glypican 3 was combined with alpha-fetoprotein. PMID: 26370140
    21. The lncRNA glypican 3 antisense transcript 1 (GPC3-AS1) has been reported to be a potential biomarker for hepatocellular carcinoma (HCC) screening. We observed a significant upregulation of GPC3-AS1 in HCC. Increased expression of GPC3-AS1 was associated with alpha-fetoprotein, tumor size, microvascular invasion, encapsulation, Barcelona Clinic Liver Cancer stage, and worse prognosis of HCC patients. PMID: 27573079
    22. study provides the first evidence that GPC3 can modulate the PCSK9 extracellular activity as a competitive binding partner to the LDLR in HepG2 cells. PMID: 27758865
    23. By subsequent Sanger sequencing of genomic DNA we could map the chromosomal break points to define a deletion size of 43,617 bp including exons 5 and 6 of the GPC3 gene. PMID: 28371070
    24. This is the first study in which the optimal HLA-A*0201 GPC3 epitopes were screened from a large number of candidates predicted by three software. The optimized HLA-A*0201 GPC3 peptides will provide new epitope candidates for hepatocellular carcinoma (HCC) immunotherapy. PMID: 27102087
    25. GPC3 and KRT19 overexpression are associated with carcinogenesis, progression, and poor prognosis in patients with PDAC and a valuable biomarker for diagnosis of PDAC. PMID: 27689616
    26. The clinical implication of GPC3 detection and targeting in the management of patients with hepatocellular carcinoma. Review. PMID: 26755876
    27. Glypican 3 expression showed a significant difference between endometrioid endometrial carcinoma and serous endometrial carcinoma, and it was significantly correlated with tumor grade, stage and myometrial invasion PMID: 26722522
    28. Data show that notum and glypican-1 and glypican-3 gene expression during colorectal cancer (CRC) development and present evidence to suggest them as potential new biomarkers of CRC pathogenesis. PMID: 26517809
    29. GPC3 expression was measured in hepatocellular carcinoma at different stages and correlated with prognosis. CK19+/GPC3+ HCC has the highest risk of intrahepatic metastasis, microvascular invasion, regional lymph node involvement, and distant metastasis. PMID: 26977595
    30. Review: Glypican-3 is a highly specific biomarker for the diagnosis of hepatocellular carcinoma and a promising therapeutic target. PMID: 26256079
    31. In South Korean hepatocellular carcinoma patients, GPC3 expression was more frequent in hepatocellular carcinoma with aggressive features, but it was not an independent prognostic biomarker. PMID: 26764243
    32. In this meta-analysis, GPC3 was found to be acceptable as a serum marker for the diagnosis of hepatocellular carcinoma. PMID: 26502856
    33. GPC3 may be a candidate marker for detecting lung squamous cell carcinoma. PMID: 26345955
    34. study suggests that GPC3 is involved in HCC cell migration and motility through HS chain-mediated cooperation with the HGF/Met pathway, showing how HS targeting has potential therapeutic implications for liver cancer PMID: 26332121
    35. potential role of GPC3 in urothelial carcinogenesis warrants further investigation, especially the potential use of Glypican-3 for therapeutic and diagnostic purposes PMID: 25896897
    36. Downregulation of glypican-3 expression increases migration, invasion, and tumorigenicity of ovarian cancer. PMID: 25967456
    37. GPC3 expression is an independent prognostic factor for postoperative hepatocellular carcinoma PMID: 25432695
    38. Identify a GPC3-specific T-cell receptor. Expression of this receptor by T cells allows them to recognize and kill GPC3-positive hepatoma cells. PMID: 26052074
    39. High expression of glypican-3 is associated hepatoblastoma. PMID: 25735325
    40. GPC3 and E-cadherin expressions are not independent prognostic factors in CRC. PMID: 25619476
    41. In HCC patients, sGPC3N levels were significantly increased (mean/median, 405.16/236.19 pg mL(-1) ) compared to healthy controls (p < 0.0001), and 60% of HCC cases (69/115) showed sGPC3N levels that were higher than the upper normal limit. PMID: 25784484
    42. GPC3 contributes to hepatocellular carcinoma progression and metastasis through impacting epithelial-mesenchymal transition of cancer cells, and the effects of GPC3 are associated with ERK activation. PMID: 25572615
    43. Most cases of hepatoblastoma and yolk sac tumor, and some cases of other tumors were found to express GPC3. On the other hand, GPC3 was physiologically expressed during the fetal and neoinfantile period under 1 year of age. PMID: 25344940
    44. OPN, SPINK1, GPC3 and KNPA2 were significantly over-expressed in HCC tissues. These genes may be useful in developing future biomarkers and therapeutic strategies for HCC PMID: 25862856
    45. Data indicate that zinc-fingers and homeoboxes 2 (ZHX2) suppresses glypican 3 (GPC3) transcription by binding with its core promoter. PMID: 25195714
    46. propose that the structural changes generated by the lack of cleavage determine a change in the sulfation of the HS chains and that these hypersulfated chains mediate the interaction of the mutant GPC3 with Ptc PMID: 25653284
    47. GPC3 is associated with the HCC cell biological behavior. PMID: 25270552
    48. Data indicate that the triple stain of reticulin, glypican-3, and glutamine synthetae is useful in the differentiation of hepatocellular carcinoma, hepatic adenoma, and focal nodular hyperplasia. PMID: 25822763
    49. Data shows that GPC3 gene expression is downregulated in primary clear cell renal cell carcinoma; its overexpression arrest cells in G1 phase suggesting its role as tumor suppressor in clear cell renal cell carcinoma. PMID: 25168166
    50. This study demonstrated that highly expression of GPC3 could enrich hepatocellular carcinoma -related genes' mRNA expression and positive associate with dysplasia in cirrhotic livers. PMID: 25542894

    顯示更多

    收起更多

  • 相關(guān)疾?。?/div>
    Simpson-Golabi-Behmel syndrome 1 (SGBS1)
  • 亞細(xì)胞定位：
    Cell membrane; Lipid-anchor, GPI-anchor; Extracellular side.
  • 蛋白家族：
    Glypican family
  • 組織特異性：
    Highly expressed in lung, liver and kidney.
  • 數(shù)據(jù)庫(kù)鏈接：

    HGNC: 4451

    OMIM: 300037

    KEGG: hsa:2719

    STRING: 9606.ENSP00000377836

    UniGene: Hs.644108